NL-OMON44826招募中3 期
A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment - AB04030
AB Science0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Histologically proven, metastatic or locally advanced non resectable, or recurrent post surgery GIST
- •2. Naïve patient or patient previously treated with imatinib as neoadjuvant/adjuvant who relapsed after
- •imatinib discontinuation
- •3. Measurable tumour lesions with longest diameter >= 20 mm using conventional techniques or >= 10 mm with
- •spiral CT scan according RECIST criteria
- •4. C-Kit (CD117) positive tumours detected by immuno-histochemically or PDGFR positive if c-kit negative
- •5. ECOG < 1
- •6. Patient with adequate organ function:
排除标准
- •1. Patient previously treated by tyrosine kinase inhibitors except imatinib in case of inclusion criteria 2
- •2. Patient treated for a cancer other than GIST within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ
- •3. Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
- •4. Patient presenting with cardiac disorders defined by at least one of the following conditions:· Patient with recent cardiac history (within 6 months) of:
- •- Acute coronary syndrome
- •- Acute heart failure (class III or IV of the NYHA classification)
- •- Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)· Patient with cardiac failure class III or IV of the NYHA classification· Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)· Syncope without known aetiology within 3 months· Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic hypertension
- •5. Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent
- •6. Patient with any condition that the physician judges could be detrimental to subjects participating in this study, including any clinically important deviations from normal clinical laboratory values or concurrent medical events
- •Previous treatment
- •7. Treatment with any investigational agent within 4 weeks prior baseline
- •8. Treatment by imatinib as neoadjuvant/adjuvant therapy within 4 weeks prior baseline
研究者
相似试验
暂停
不适用
A study to evaluate the efficacy and safety of Aceinavir combined with supportive Standard of Care (SoC) in hospitalized patients with moderate coronavirus disease (COVID-19)CTRI/2020/08/027284Dyuthi Biosciences Private Limited
进行中（未招募）
1 期
A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmentGastro-intestinal stromal tumour (GIST)MedDRA version: 17.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000973-40-GRAB SCIENCE450
进行中（未招募）
1 期
A study to compare masitinib with dacarbazine in the treatment of patients with advanced melanoma carrying a mutation in a gene called c-kitEUCTR2009-017918-69-HUAB Science112
进行中（未招募）
1 期
A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmentEUCTR2008-000973-40-ATAB SCIENCE450
进行中（未招募）
1 期
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmentgastro-intestinal stromal tumourMedDRA version: 9.1 Level: LLT Classification code 10051066 Term: Gastrointestinal stromal tumourEUCTR2008-000973-40-FRAB SCIENCE222